Sign in
Active, not recruitingNo phase

Clinical Study to Confirm the Safety and Performance of the Virtuoso Phaco-vitrectomy Device

Key facts

Who runs it
Beaver-Visitec International, Inc.
Where
Germany1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
205 people, planned
Started
3 Dec 2025
Expected to end
Nov 2026
Type of study
Observational, 3 groups
Record updated
1 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Primary or repeat vitrectomy (only applicable to patients scheduled for vitrectomy or combined procedure)
  • Patients aged ≥ 18 years
  • Willing and able to provide written informed consent for participation in the study
  • Willing and able to comply with scheduled visits and other study procedures

Who cannot take part

  • Patients with ocular comorbidities affecting surgical view including corneal opacities or scar
  • Participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial
  • History of intraocular inflammation
  • Untreated diabetes
  • Pre-operative endothelial cell count <1500 cells/cm2 (only applicable to patients considered for the cataract subgroup or the combined surgeries subgroup)
  • Patients aged < 18 years
  • No post-operative 90 days visit is anticipated
  • Patients requiring or having already had scleral buckling
  • Advanced and secondary glaucoma
  • Microphthalmos or macrophthalmos
  • Post-Traumatic eye
  • Subluxated lens
  • Morganian cataract
  • Weak zonules: zonuli lysis or zonula laxa manifest
  • Pregnant or nursing females

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a pre-market clinical investigation with a device that does not bear the CE-marking. Aim of the study is to confirm the safety and performance of the device and collect user feedback.

The 3 groups in the trial

  • Cataract subgroup

    The patients recruited in this subgroup will undergo their routine cataract surgery. The Vitrectomy device will be used during surgery during the phacoemulsification phase of the surgery.

  • Pars-plana Vitrectomy subgroup

    The patients in this group will undergo the pars-plana vitrectomy surgery prescribed by their eye doctor. The device will be used to remove the vitreous humor and/or scar tissue which affect the retina.

  • Combined PPV and Cataract Subgroup

    The patients included in this group will undergo combined surgery as recommended by their eye doctor. The device will be used for the phacoemulsification and pars-plana vitrectomy phases of the surgery.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
1 July 2026